Potential role of sorafenib as neoadjuvant therapy in unresectable papillary thyroid cancer

Potential role of sorafenib as neoadjuvant therapy in unresectable papillary thyroid cancer

Summary Total thyroidectomy, radioiodine (RAI) therapy, and TSH suppression are the mainstay treatment for differentiated thyroid carcinomas (DTCs). Treatments for metastatic disease include surgery, external-beam radiotherapy, RAI, and kinase inhibitors for progressive iodine-refractory disease. Un...

Full description

Bibliographic Details
Main Authors:	Debora L. S. Danilovic, Gilberto Castro Jr., Felipe S. R. Roitberg, Felipe A. B. Vanderlei, Fernanda A. Bonani, Ricardo M. C. Freitas, George B. Coura-Filho, Rosalinda Y. Camargo, Marco A. Kulcsar, Suemi Marui, Ana O. Hoff
Format:	Article
Language:	English
Published:	Brazilian Society of Endocrinology and Metabolism 2018-05-01
Series:	Archives of Endocrinology and Metabolism
Online Access:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S2359-39972018000300370&lng=en&tlng=en

Similar Items

Critical analysis of molecular tests in indeterminate thyroid nodules
by: Debora L. S. Danilovic, et al.

Prevalence of DICER1 variants in large multinodular goiter: thyroid function, clinical and imaging characteristics
by: Lara Judith Cabral Miranda, et al.
Published: (2024-02-01)

Sorafenib for the treatment of unresectable hepatocellular carcinoma
by: Junji Furuse
Published: (2008-11-01)

Diagnostic performance of thyroid ultrasound in Hürthle cell carcinomas
by: Nathalie Oliveira Santana, et al.
Published: (2019-04-01)

Unresectable Ectopic Hepatocellular Carcinoma Treated with Sorafenib
by: Yi-Ling Ko, et al.
Published: (2020-04-01)

25-Hydroxyvitamin D and TSH as Risk Factors or Prognostic Markers in Thyroid Carcinoma.
by: Debora Lucia Seguro Danilovic, et al.
Published: (2016-01-01)

Thyroid collision tumor containing oncocytic carcinoma, classical and hobnail variants of papillary carcinoma and areas of poorly differentiated carcinoma
by: Marcos Tadashi Kakitani Toyoshima, et al.
Published: (2021-07-01)

Impact of lenvatinib on renal function compared to sorafenib for unresectable hepatocellular carcinoma
by: Ryu Sasaki, MD, PhD, et al.
Published: (2022-05-01)

Thymic hyperplasia in graves’ disease
by: Debora Lucia Seguro Danilovic, et al.
Published: (2011-01-01)

Survival Outcomes for Yttrium-90 Transarterial Radioembolization With and Without Sorafenib for Unresectable Hepatocellular Carcinoma Patients
by: Teyateeti A, et al.
Published: (2020-09-01)

Neoadjuvant chemotherapy in technically unresectable adenocarcinoma of parotid
by: Sachin Dhumal, et al.
Published: (2019-01-01)

Thyroid hormonal disturbances related to treatment of hepatitis C with interferon-alpha and ribavirin
by: Debora Lucia Seguro Danilovic, et al.
Published: (2011-01-01)

Neoadjuvant Multikinase Inhibitor in Patients With Locally Advanced Unresectable Thyroid Carcinoma
by: Carla Fernanda Nava, et al.
Published: (2019-10-01)

Potential Therapeutic Agents against Paclitaxel—And Sorafenib-Resistant Papillary Thyroid Carcinoma
by: Seok-Mo Kim, et al.
Published: (2022-09-01)

Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy
by: Burgio V, et al.
Published: (2021-12-01)

Clinical impact of lenvatinib in patients with unresectable hepatocellular carcinoma who received sorafenib
by: Yen-Yang Chen, et al.
Published: (2020-11-01)

Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma: Preliminary Toxicity and Activity Data in Dogs
by: Laura Marconato, et al.
Published: (2020-05-01)

Durable objective response to sorafenib and role of sequential treatment in unresectable hepatocellular carcinoma
by: Kuo-Wei Huang, et al.
Published: (2022-05-01)

Anti-Cancer SERCA Inhibitors Targeting Sorafenib-Resistant Human Papillary Thyroid Carcinoma
by: Hang-Seok Chang, et al.
Published: (2023-04-01)

Determinants of Survival and Post-Progression Outcomes by Sorafenib–Regorafenib Sequencing for Unresectable Hepatocellular Carcinoma
by: I-Cheng Lee, et al.
Published: (2022-04-01)

Combination therapy of sorafenib and TACE for unresectable HCC: a systematic review and meta-analysis.
by: Lei Liu, et al.
Published: (2014-01-01)

Erratum to “Durable Objective Response to Sorafenib and Role of Sequential Treatment in Unresectable Hepatocellular Carcinoma”
Published: (2022-07-01)

Accelerated Disease Progression after Discontinuation of Sorafenib in a Patient with Metastatic Papillary Thyroid Cancer
by: Kyung-Jin Yun, et al.
Published: (2014-09-01)

Neoadjuvant Chemotherapy with Capecitabine and Temozolomide for Unresectable Pancreatic Neuroendocrine Tumor
by: Sumana Devata, et al.
Published: (2012-11-01)

Cost-effectiveness analysis of Tislelizumab vs Sorafenib as the first-line treatment of unresectable hepatocellular carcinoma
by: Qiuping Chen, et al.
Published: (2024-01-01)

Safety assessment of sorafenib in Chinese patients with unresectable hepatocellular carcinoma: subgroup analysis of the GIDEON study
by: Sheng-Long Ye, et al.
Published: (2018-03-01)

TACE-Sorafenib With Thermal Ablation Has Survival Benefits in Patients With Huge Unresectable Hepatocellular Carcinoma
by: Ying Wu, et al.
Published: (2020-07-01)

Active surveillance of papillary thyroid microcarcinomas in South America: Are we ready?
by: Debora Lucia Seguro Danilovic, et al.
Published: (2019-10-01)

Discovery of New Anti-Cancer Agents against Patient-Derived Sorafenib-Resistant Papillary Thyroid Cancer
by: Yuna Kim, et al.
Published: (2023-11-01)

Real-World Effectiveness of Sorafenib versus Lenvatinib Combined with PD-1 Inhibitors in Unresectable Hepatocellular Carcinoma
by: Hsueh-Chien Chiang, et al.
Published: (2023-01-01)

Clinical usefulness of geriatric assessment in elderly patients with unresectable hepatocellular carcinoma receiving sorafenib or lenvatinib therapy
by: Shuhei Sekiguchi, et al.
Published: (2022-11-01)

Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis
by: Lin Li, et al.
Published: (2018-09-01)

Regorafenib for Taiwanese patients with unresectable hepatocellular carcinoma after sorafenib failure: Impact of alpha‐fetoprotein levels
by: Po‐Yao Hsu, et al.
Published: (2022-01-01)

The Cost Effectiveness of Donafenib Compared With Sorafenib for the First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma in China
by: Rui Meng, et al.
Published: (2022-03-01)

Rechallenge with Lenvatinib after Refractoriness to Initial Lenvatinib Followed by Sorafenib in a Patient with Metastatic Papillary Thyroid Carcinoma
by: Masaki Takinami, et al.
Published: (2020-05-01)

2-Deoxy-d-Glucose Can Complement Doxorubicin and Sorafenib to Suppress the Growth of Papillary Thyroid Carcinoma Cells.
by: Shuo-Yu Wang, et al.
Published: (2015-01-01)

A Real-World Comparative Analysis of Lenvatinib and Sorafenib as a Salvage Therapy for Transarterial Treatments in Unresectable HCC
by: Jaejun Lee, et al.
Published: (2020-12-01)

Cost‐effectiveness analysis of sintilimab plus IBI305 versus sorafenib for unresectable hepatic cell carcinoma in China
by: Zhe Xu, et al.
Published: (2023-07-01)

Baseline and Early Predictors of Good Patient Candidates for Second-Line after Sorafenib Treatment in Unresectable Hepatocellular Carcinoma
by: Hitomi Takada, et al.
Published: (2019-08-01)

Callispheres drug-eluting bead transhepatic artery chemoembolization with oral delivery of sorafenib for the treatment of unresectable liver cancer
by: Wenhui Wang, et al.
Published: (2022-09-01)